RMC-6291   Click here for help

GtoPdb Ligand ID: 12622

Compound class: Synthetic organic
Comment: RMC-6291 is a tri-complex KRASG12C(ON) inhibitor, that was developed for anti-tumour potential. It inhibits active, GTP-bound RAS. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 meeting of the AACR in Orlando.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 17
Hydrogen bond donors 2
Rotatable bonds 13
Topological polar surface area 168.9
Molecular weight 1012.26
XLogP 5.49
No. Lipinski's rules broken 3
Click here for help
Canonical SMILES CCN1C2=CC=C3C=C2C(=C1C4=C([C@H](C)OC)N=CC=C4)CC(C)(C)COC(=O)[C@@H]5CCCN(C(=O)[C@@H](C[C@H]6CN3CCO6)NC(=O)[C@H](C(C)C)N(C)C(=O)C7(CCN(CC7)C(=O)C#CC(C)(C)N(C)C)F)N5
Isomeric SMILES CCN1C2=C3C=C(C=C2)N4CCO[C@H](C4)C[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)C5(F)CCN(CC5)C(=O)C#CC(C)(C)N(C)C)C(=O)N6CCC[C@H](N6)C(=O)OCC(C)(C)CC3=C1C7=C(N=CC=C7)[C@H](C)OC
InChI InChI=1S/C55H78FN9O8/c1-13-64-44-19-18-37-30-40(44)41(48(64)39-16-14-24-57-46(39)36(4)71-12)32-53(5,6)34-73-51(69)42-17-15-25-65(59-42)50(68)43(31-38-33-63(37)28-29-72-38)58-49(67)47(35(2)3)61(11)52(70)55(56)22-26-62(27-23-55)45(66)20-21-54(7,8)60(9)10/h14,16,18-19,24,30,35-36,38,42-43,47,59H,13,15,17,22-23,25-29,31-34H2,1-12H3,(H,58,67)/t36-,38-,42-,43+,47-/m0/s1
No information available.
Summary of Clinical Use Click here for help
RMC-6291 has been advanced to early stage clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05462717 Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1 Interventional Revolution Medicines, Inc.